8-K: Co-Diagnostics Reports Full Year 2023 Results Amidst COVID-19 Test Demand Decline

Co-Diagnostics reported a significant decrease in revenue for 2023 due to reduced demand for COVID-19 tests, alongside increased investment in new platform development.

Summary

• Co-Diagnostics announced its financial results for the full year ended December 31, 2023, revealing a revenue of $6.8 million, a substantial decrease from $34.2 million in the prior year.
• This decline is primarily attributed to a drop in global demand for the company's Logix Smart COVID-19 tests.
• The company's operating expenses decreased by 18.6% to $45.3 million, mainly due to reduced goodwill impairment charges, but this was offset by increased research and development costs.
• Co-Diagnostics reported an operating loss of $42.7 million, compared to a $27.0 million loss in 2022.
• The net loss for the year was $35.3 million, or $1.20 per fully diluted share, compared to a net loss of $14.2 million, or $0.45 per share, in the previous year.
• Adjusted EBITDA loss was $33.0 million.
• The company repurchased approximately 967,000 shares of common stock at an average price of $1.41 per share, totaling about $1.4 million.
• As of December 31, 2023, Co-Diagnostics had $58.5 million in cash, cash equivalents, and marketable securities.
• The company received $12.6 million in grant funding in 2023 to support the development of tests for tuberculosis, upper respiratory multiplex, and human papillomavirus.

Sentiment

Score: 3

Explanation: The document presents a challenging financial picture with significant revenue decline and increased losses, despite positive developments in new product development and grant funding. The overall sentiment is negative due to the poor financial performance.

Positives

• The company secured $12.6 million in grant funding to support the development of new diagnostic tests.
• Co-Diagnostics submitted an EUA to the FDA for its Co-Dx PCR Pro instrument, mobile app, and COVID-19 test kit.
• The company appointed a new Chief Regulatory Affairs Officer with extensive experience.
• The company has built a new manufacturing facility to support production of test cups and Co-Dx PCR Pro instruments.
• The company repurchased approximately 967,000 shares of common stock, indicating confidence in its future.

Negatives

• Revenue significantly decreased from $34.2 million to $6.8 million due to reduced demand for COVID-19 tests.
• The company experienced a substantial operating loss of $42.7 million, compared to a $27.0 million loss in the previous year.
• Net loss increased to $35.3 million, or $1.20 per fully diluted share, from $14.2 million, or $0.45 per share, in the prior year.
• The company reported an adjusted EBITDA loss of $33.0 million.

Risks

• The company's financial performance is heavily reliant on the success of its new Co-Dx PCR platform, which is still subject to regulatory review.
• The decline in COVID-19 test demand poses a significant challenge to the company's revenue stream.
• The company is incurring significant losses, which may impact its ability to fund future operations and growth.
• The company's new products are subject to FDA approval, and there is no guarantee that they will be approved or commercially successful.

Future Outlook

Co-Diagnostics plans to continue the development of its TB, multiplex respiratory, and HPV tests throughout 2024 and anticipates providing updates on its test development and platform. The company believes its EUA submission will serve as a steppingstone in its effort to decentralize PCR diagnostics and expand to point-of-care and at-home settings.

Management Comments

• We are pleased to have made great progress towards our strategic goals in the fourth quarter, highlighted by an Emergency Use Authorization submission to the FDA for our Co-Dx PCR Pro instrument, mobile app, and COVID-19 test, said Dwight Egan, Co-Diagnostics Chief Executive Officer.
• Co-Diagnostics investment in additional production capacity in Salt Lake City also includes the manufacturing of our Co-Primers in-house, to lower costs.
• We are currently building expanded capacity for test cup and instrument manufacturing lines in India as well, in addition to capability to support Co-Primers manufacturing in the near future.
• We remain excited for 2024 and look forward to providing updates on our test development and platform, said Brian Brown, Co-Diagnostics Chief Financial Officer.

Industry Context

The decline in COVID-19 test demand reflects a broader trend in the diagnostics industry as the pandemic transitions to an endemic phase. Co-Diagnostics is pivoting towards new diagnostic tests and platforms to address this shift, aligning with the industry's focus on diversified testing solutions.

Comparison to Industry Standards

• The significant drop in revenue from COVID-19 testing is consistent with trends seen in other diagnostic companies that experienced a surge in demand during the pandemic, such as QuidelOrtho and Abbott, which have also reported declines in COVID-19 related revenue.
• The shift towards point-of-care and at-home testing aligns with industry trends, with companies like Cue Health and Lucira Health also focusing on decentralized testing solutions.
• The investment in new manufacturing facilities and R&D is similar to strategies employed by companies like Roche and Thermo Fisher Scientific, which are continuously expanding their diagnostic capabilities.
• The adjusted EBITDA loss of $33.0 million is a significant concern, especially when compared to companies with more diversified revenue streams and established market positions.

Management Changes

Stakeholder Impact

• Shareholders will be negatively impacted by the significant losses and decreased revenue.
• Employees may be affected by potential cost-cutting measures due to the financial challenges.
• Customers may benefit from the development of new diagnostic tests, but the availability of these tests is subject to regulatory approval.
• Suppliers may experience reduced demand due to the company's decreased revenue.

Next Steps

• Co-Diagnostics plans to continue the development of its TB, multiplex respiratory, and HPV tests throughout the year.
• The company will provide updates on its test development and platform.
• The company will continue to seek regulatory approvals for its new products.

Key Dates

Keywords

Co-Diagnostics, Molecular Diagnostics, PCR, COVID-19, EUA, FDA, Tuberculosis, HPV, Respiratory Panel, Financial Results, Point-of-Care, At-Home Testing